Investing in Outlook Therapeutics involves significant biopharmaceutical risks, including potential commercialization hurdles, heavy reliance on the successful market adoption of its flagship eye drug, the necessity for future capital raises or debt financing, and the high volatility typical of small-cap biotech equities navigating competitive healthcare markets.